Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly

Summary

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (MONDO:0017346) is a cancer and 2 clinical trials. Top therapeutic interventions include selinexor. A subtype of Epstein-Barr virus-associated lymphoproliferative disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly
Mondo ID	MONDO:0017346
Orphanet	289661
ICD-11	407807101
NCIT	C80281
SNOMED CT	716788007
UMLS	C2700007
MedGen	397690
GARD	0021150
Is cancer (heuristic)	yes

Also known as: age-related EBV Positive B-cell lymphoproliferative disorder · EBV Positive diffuse large B-cell lymphoma of the elderly · EBV-Positive diffuse large B-cell lymphoma, NOS · EBV-positive DLBCL of the elderly · Epstein-Barr Virus Positive diffuse large B-cell lymphoma of the elderly · Senile EBV-associated B-cell lymphoproliferative disorder

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › virus associated tumor › Epstein-Barr virus-related tumor › Epstein-Barr virus-associated lymphoproliferative disorder › Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly

Related subtypes (10): primary central nervous system lymphoma, Hodgkins lymphoma, Burkitt lymphoma, plasmablastic lymphoma, diffuse large B-cell lymphoma with chronic inflammation, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, hydroa vacciniforme-like lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, extranodal nasal NK/T cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06925555	PHASE2	NOT_YET_RECRUITING	Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
NCT05577364	PHASE1/PHASE2	UNKNOWN	Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SELINEXOR	4	1